請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10650
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙(Tony Hsiu-Hsi Chen) | |
dc.contributor.author | Yi-Chia Lee | en |
dc.contributor.author | 李宜家 | zh_TW |
dc.date.accessioned | 2021-05-20T21:46:50Z | - |
dc.date.available | 2015-09-09 | |
dc.date.available | 2021-05-20T21:46:50Z | - |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-05 | |
dc.identifier.citation | 1.Bolye P, Levin B (2008). World cancer report. Lyon, France: IARC press.
2.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. 3.A snapshot of stomach (gastric) cancer. National Cancer Institute. Available at http://www.cancer.gov/aboutnci/servingpeople/cancer-snapshots. Assessed on March 1, 2010 4.Matsuzaka M, Fukuda S, Takahashi I, et al. The decreasing burden of gastric cancer in Japan. Tohoku J Exp Med 2007;212:207-19. 5.Lee HJ, Yang HK, Ahn YO. Gastric cancer in Korea. Gastric Cancer 2002;5:177-82. 6.Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006;12:17-20. 7.Cancer Statistics. Taiwan Cancer Registry. Available at: http://crs.cph.ntu.edu.tw/main.php. Assessed on March 1, 2010. 8.Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990;50:4737-40. 9.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40. 10.Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8. 11.Ruiz B, Garay J, Correa P, et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281-7. 12.Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40. 13.Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7-14. 14.Zhou L, Sung JJ, Lin S, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11-4. 15.Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomized trial on Helicobacter pylori eradication. Gut 2004;53:1244-9. 16.Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-69. 17.You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83. 18.Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 2004;57:177-82. 19.Liu TY, Wu CY, Lin JT, et al. Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen 2006;13 Suppl 1:S2-5. 20.de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945-52. 21.Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1(8390):1311-5. 22.Huang JQ, Sridhar S, Chen Y, et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-79. 23.Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999;94:2373-9. 24.Xue FB, Xu YY, Wan Y, et al. Association of H. pylori infection with gastric carcinoma: a meta-analysis. World J Gastroenterol 2001;7:801-4. 25.Wang C, Yuan Y, Hunt RH. The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am J Gastroenterol 2007;102:1789-98. 26.Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53. 27.Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8. Erratum in: Ann Intern Med 2009;151:516. 28.行政院衛生署科技研究計畫: 95年至97年馬祖及其台灣移民之胃癌預防性介入計畫成果報告書。台灣篩檢學會。 29.Lin DB, Lin JB, Chen CY, Chen SC, Chen WK. Seroprevalence of Helicobacter pylori infection among schoolchildren and teachers in Taiwan. Helicobacter 2007;12:258-64. 30.Hsu PI, Lai KH, Hsu PN, et al. Helicobacter pylori infection and the risk of gastric malignancy. Am J Gastroenterol 2007;102:725-30. 31.伍超群、張耀仁、林憲宏等人。分析台灣東部漢人和原住民幽鬥桿菌臨床分離株之致病基因與臨床相關性。慈濟醫學雜誌。2004;16:33-42。 32.Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut 2007;56:772-81. 33.Zhang YY, Xia HH, Zhuang ZH, Zhong J. Review article: 'true' re-infection of Helicobacter pylori after successful eradication - worldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther 2009;29:145-60. 34.Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9. 35.Sugano K, Sato K, Yao K. New diagnostic approaches for early detection of gastric cancer. Dig Dis 2004;22:327-33. 36.Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94. 37.Guo HQ, Guan P, Shi HL, et al. Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol 2003;9:432-6. 38.Moayyedi P, Feltbower R, Crocombe W, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 2000;14:719-28. 39.Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomized controlled trial. Leeds HELP Study Group. Lancet 2000;355(9216):1665-9. 40.Ford AC, Forman D, Bailey AG, et al. A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005;129:1910-7. 41.Lane JA, Harvey RF, Murray LJ, et al. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population: study design and response rates of the Bristol Helicobacter Project. Control Clin Trials 2002;23:321-32. 42.Lane JA, Murray LJ, Noble S, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomized controlled trial. BMJ 2006;332(7535):199-204. 43.Harvey RF, Lane JA, Murray LJ, et al. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol helicobacter project. BMJ 2004;328:1417-20. 44.Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and retreat initial treatment failures. Helicobacter 2006;11:418-24. 45.Lee YC, Chen TH, Chang SH, et al. Can Helicobacter pylori eradication reduce the premalignant gastric lesions? A population-based gastric cancer chemoprevention study. Manuscript in preparation. 46.Lee YC, Lin JT, Chen TH, Wu MS. Is eradication of Helicobacter pylori the feasible way to prevent gastric cancer? New evidence and progress, but still a long way to go. J Formos Med Assoc 2008;107:591-9. 47.Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005;54:735-8. 48.Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9. 49.Willyard C. A tough controversy to stomach. Nat Med 2009;15:836-9. 50.Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003;52:637-40. 51.Furuta T, Shirai N, Xiao F, et al. Effect of Helicobacter pylori infection and its eradication on nutrition. Aliment Pharmacol Ther 2002;16:799-806. 52.Konturek PC, Cześnikiewicz-Guzik M, Bielanski W, et al. Involvement of Helicobacter pylori infection in neuro-hormonal control of food intake. J Physiol Pharmacol 2006;57 Suppl 5:67-81. 53.Wu MS, Lee WJ, Wang HH, et al. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med 2005;165:1552-5. 54.Blaser MJ, Chen Y, Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut 2008;57:561-7. 55.Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999;13:155-62. 56.Hamada H, Haruma K, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000;14:729-35. 57.Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002;97:2992-7. 58.Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:279-89. Retraction in Aliment Pharmacol Ther 2004;19:145. 59.Raghunath AS, Hungin AP, Wooff D, Childs S. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733-44. Review. 60.Güliter S, Kandilci U. The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. J Clin Gastroenterol 2004;38:750-5. 61.Ott EA, Mazzoleni LE, Edelweiss MI, et al. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther 2005;21:1231-9. 62.Yaghoobi M, Farrokhyar F, Yuan Y, Hunt RH. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am J Gastroenterol 2010;105:1007-13. 63.Yang YJ, Sheu BS, Chang WL, Cheng HC, Yang HB. Increased body mass index after H. pylori eradication for duodenal ulcer predisposes to erosive reflux esophagitis. J Clin Gastroenterol 2009;43:705-10. 64.Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80. 65.Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control 2010;21:269-74. 66.Yee YK, Cheung TK, Chan AO, Yuen MF, Wong BC. Decreasing trend of esophageal adenocarcinoma in Hong Kong. Cancer Epidemiol Biomarkers Prev 2007;16:2637-40. 67.Fernandes ML, Seow A, Chan YH, Ho KY. Opposing trends in incidence of esophageal squamous cell carcinoma and adenocarcinoma in a multi-ethnic Asian country. Am J Gastroenterol 2006;101:1430-6. 68.Kusano C, Gotoda T, Khor CJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol 2008;23:1662-5. 69.Chung JW, Lee GH, Choi KS, et al. Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification. Dis Esophagus 2009;22:676-81. 70.Goh KL, Wong HT, Lim CH, Rosaida MS. Time trends in peptic ulcer, erosive reflux oesophagitis, gastric and oesophageal cancers in a multiracial Asian population. Aliment Pharmacol Ther 2009;29:774-80. 71.Chang CY, Cook MB, Lee YC, et al; and the Asian Barrett’s Consortium. Current status of Barrett’s esophagus research in Asia. J Gastroenterol Hepatol. In press. 72.Chen MJ, Lee YC, Chiu HM, Wu MS, Wang HP, Lin JT. Time trends of endoscopic and pathological diagnoses related to gastroesophageal reflux disease in a Chinese population: eight years single institution experience. Dis Esophagus 2010;23:201-7. 73.Fass R. Distinct phenotypic presentations of gastroesophageal reflux disease: a new view of the natural history. Dig Dis 2004;22:100-107. 74.Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol 2002;97:1901-9. 75.Pace F, Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004;99:946-9. 76.Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002;17:949–54. 77.Pace F, Bollani S, Molteni P, et al. Natural history of gastroesophageal reflux disease without oesophagitis (NERD)—a reappraisal 10 years on. Dig Liver Dis 2004;36:111–115. 78.Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006;101:2457-62. 79.Malfertheiner P, Nocon M, Höcker MR, et al. How dose GERD evolve during a 5-year follow-up period? The ProGERD study [abstract]. Gastroenterology 2008;134:A592. 80.Sontag SJ, Sonnenberg A, Schnell TG, et al. The long-term natural history of gastroesophageal reflux disease. J Clin Gastroenterol 2006;40:398-404. 81.Ronkainen J, Aro P, Storskrubb T, et al. Natural history of NERD in the general population, the Kalixanda study. Gastroenterology 2009;134:A74-5. 82.Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009;58:174-81. 83.Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91,1391.e1-5. 84.Lee YC, Wang HP, Chiu HM, et al. Comparative analysis between psychological and endoscopic profiles in patients with gastroesophageal reflux disease: A prospective study based on screening endoscopy. J Gastroenterol Hepatol 2006;21:798-804. 85.Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population. J Clin Gastroenterol 2008;42:1074-9. 86.Tai CM, Lee YC, Wu MS, et al. The effect of Roux-en-Y gastric bypass on gastroesophageal reflux disease in morbidly obese Chinese patients. Obes Surg 2009;19:565-70. 87.Souza RC, Lima JH. Helicobacter pylori and gastroesophageal reflux disease: a review of this intriguing relationship. Dis Esophagus 2009;22:256-63. 88.Chen TH, Kuo HS, Yen MF, et al. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 2000;56:167-72. 89.Chen CD, Yen MF, Wang WM, Wong JM, Chen TH. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 2003;88:1866-73. 90.Pan SL, Lien IN, Yen MF, Lee TK, Chen TH. Dynamic aspect of functional recovery after stroke using a multistate model. Arch Phys Med Rehabil 2008;89:1054-60. 91.Cox DR, Miller HD (1965). The Theory of Stochastic Processes. London: Methuen. 92.Kalbfleisch JD, Lawless JF. The analysis of panel data under a Markov assumption. J Am Stat Assoc 1985;80:863-71. 93.Yen AMF, Chen TH. Mixture multi-state Markov regression model. J Appl Stat 2007;34:11-21. 94.Wu MS, Chen CJ, Lin JT. Host-environmental interactions: Their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1878-82. 95.Chang YJ, Wu MS, Lin JT, et al. Mechanisms for Helicobacter pylori CagA-induced cyclin D1 expression that affect cell cycle. Cell Microbiol 2006;8:1740-52. 96.Lu H, Yamaoka Y, Graham DY. Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 2005;21:653-9. 97.El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 2000;118:22-30. 98.Sheu BS, Yang HB, Sheu SM, et al. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003;9:5245-51. 99.Wu CY, Kuo KN, Wu MS, et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-8. 100.Hamajima N, Naito M, Kondo T, Goto Y. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 2006;97:1129-38. 101.Gianfagna F, De Feo E, van Duijn CM, Ricciardi G, Boccia S. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 2008;9:361-74. 102.Wang J, Pan HF, Hu YT, Zhu Y, He Q. Polymorphism of IL-8 in 251 allele and gastric cancer susceptibility: A meta-analysis. Dig Dis Sci 2010;55:1818-23. 103.Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007;121:1481-6. 104.Boccia S, Hung R, Ricciardi G, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am J Epidemiol 2008;167:505-16. 105.Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW. The E-cadherin gene polymorphism 160C->A and cancer risk: A HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 2008;167:7-14. 106.Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer 2004;7:61-77. 107.Wu MS, Shun CT, Lee WC, et al. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 1998;78:971-3. 108.Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000;156:537-43. 109.Issa JP. Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res (Phila Pa) 2008;1:219-22. 110.Nakajima T, Enomoto S, Ushijima T. DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med 2008;13:8-15. 111.Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 2006;12(3 Pt 1):989-95. 112.Nakajima T, Enomoto S, Yamashita S, et al. Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication. J Gastroenterol 2010;45(1):37-44. 113.Miki K, Ichinose M, Ishikawa KB, et al. Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086-90. 114.Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141-7. 115.Lin YF, Wu MS, Chang CC, et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol Cell Proteomics 2006;5:1484-96. 116.Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308. 117.Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415-30. 118.Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 2007;25:807-16. 119.Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of 'community acquired' syncope. BMC Health Serv Res 2006;6:68. 120.Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4. 121.Fendrick AM, Chernew ME, Hirth RA, et al. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999;159:142-8. 122.Harris RA, Owens DK, Witherell H, et al. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter 1999;4:69-76. 123.Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68. 124.Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003;10:148-56. 125.Wang Q, Jin PH, Lin GW, et al. Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:135-9. 126.Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007;16:875-85. 127.Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. World J Gastroenterol 2008;14:3021-7. 128.Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 2009;124:157-66. 129.Chen TH. Risk assessment with multi-state model for gastric cancer: personalized prevention strategy. Lecture on Singapore Gastric Cancer Consortium (SGCC) 2009. Manuscript in preparation. 130.Balas EA, Kretschmer RA, Gnann W, et al. Interpreting cost analyses of clinical interventions. JAMA 1998;279:54-7. 131.Ramsey S. Gut check: can cost-effectiveness analysis help eliminate gastric cancer in Asia? Cancer Epidemiol Biomarkers Prev 2007;16:873-4. 132.Chen SY, Liu TY, Shun CT, et al. Modification effects of GSTM1, GSTT1 and CYP2E1 polymorphisms on associations between raw salted food and incomplete intestinal metaplasia in a high-risk area of stomach cancer. Int J Cancer 2004;108:606-12. 133.Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model: design, implementation, and analysis of 42,387 participants. Cancer 2004;100:1734-43. 134.胃癌多階段多因子模式探討:馬祖地區社區胃癌篩檢。國立臺灣大學預防醫學研究所民國91年碩士論文。研究生:劉增應,指導教授:陳秀熙教授;陳建仁教授。 135.以幽門桿菌除菌治療為基礎之胃癌初段預防及其成本效果分析。國立臺灣大學預防醫學研究所民國94年碩士論文。研究生:李宜家,指導教授:陳秀熙教授;林肇堂教授。 136.Cook TD, Campbell DT (1979). Quasi-Experiments: Interrupted Time-Series Designs. In: Quasi-Experimentation: Design & Analysis Issues for Field Settings. Houghton Mifflin Co, Boston. 137.Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81. 138.Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74. 139.Rosner B (2005). Hypothesis Testing: Person-Time Data. Fundamentals of Biostatistics. Duxbury Press. 140.戴政、江淑瓊 (2004). 生物醫學統計概論。翰蘆圖書出版有限公司。 141.Tan CE, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6. 142.Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population. J Clin Gastroenterol 2008;42:1074-9. 143.Lee YC, Lin JT, Chiu HM, et al. Intraobserver and interobserver consistency for grading esophagitis with narrow-band imaging. Gastrointest Endosc 2007;66(2):230-6. 144.Lee YC, Cook MB, Bhatia S, et al. Inter-observer agreement in the diagnosis of endoscopically suspected Barrett’s esophagus: an Asian multinational study. Endoscopy 2010. In press. 145.Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9. 146.Chao TK, Chen TH. Predictive model for progression of hearing loss: meta-analysis of multi-state outcome. J Eval Clin Pract 2009;15:32-40. 147.Wu HM, Yen MF, Chen TH. SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression. Comput Methods Programs Biomed 2004;75:95-105. 148.Lee YC, Wang CP, Chen CC, et al. Transnasal endoscopy with narrow-band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscope (with video). Gastrointest Endosc 2009;69(3 Pt 1):408-17. 149.Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, and Boyle P, eds (2007). Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160, Lyon, IARC. 150.Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007;25:805-12. 151.Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 2008;42:279-83. 152.Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007;117:60-9. 153.Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10. 154.de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter 2007;12:1-15. 155.Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002;51:885-92. 156.Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211. 157.Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41. 158.Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower oesophageal sphincter relaxation. Gastroenterology 2007;132:883-889. 159.Tai CM, Lee YC, Tu HP, et al. The relationship between visceral adiposity and the risk of erosive esophagitis in morbidly obese Chinese patients. Obesity 2010. In press. 160.Gudlaugsdottir S, Verschuren W, Dees J, et al. Hypertension is frequently present in patients with reflux esophagitis or Barrett's esophagus but not in those with non-ulcer dyspepsia. Eur J Intern Med 2002;13:369-75. 161.Moki F, Kusano M, Mizuide M, et al. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther 2007;26:1069-75. 162.Chung SJ, Kim D, Park MJ, et al. Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 health check-up Koreans. Gut 2008;57:1360-5. 163.Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965-71. 164.Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Moreira-Dias L. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 2007;22:1594-604. 165.Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc. 2010 Apr 27. [Epub ahead of print] | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/10650 | - |
dc.description.abstract | 幽門螺旋桿菌除菌治療可降低胃黏膜的發炎反應,然而族群性大規模除菌治療對於預防胃癌之效益目前仍然未知,本論文第一章節首先使用干涉時間序列設計量化除菌治療對於對於胃癌自然病史之影響。於1995–1999、2004、以及2008年計劃針對胃癌高風險之馬祖居民施行之大規模內視鏡篩檢及胃黏膜組織切片檢查,並於2004及2008年全面篩檢及治療幽門螺旋桿菌感染,研究目的為量化預防胃癌及癌前病變之效益。結果顯示除菌治療降低細菌盛行率之效益為91.4% (95%信賴區間 [CI]: 89.3–93.4%),細菌再發率為每人年1% (95%CI: 0.6–1.4%),在幽門螺旋桿菌除菌治療前,胃萎縮發生率為每人年8.2% (95%CI: 6–10.3%),治療後發生率下降至每人年3.5% (95%CI: 1–6.1%),相對風險為 0.434 (95%CI: 0.194–0.951),預防胃萎縮之效益估計為57% (P=0.02)。而腸組織化生於除菌前發生率為每人年4.7% (95%CI: 3.1–6.2%),於除菌治療後,其發生率略升為每人年6.1% (95%CI: 5–7.1%),相對風險估計為1.291 (95%CI: 0.881–1.891),代表此介入無法預防腸組織化生。針對胃癌,除菌治療之前1999–2003年之五年平均胃癌發生率每十萬人年40.3 (95%CI: 20.6–60.0),於除菌治療之後,2004–2008年五年平均胃癌發生率為每十萬人年30.4 (95%CI: 15.0-45.7),相對風險為0.753 (95%CI: 0.372–1.524),介入之效益為25%,但未達顯著水準 (P=0.21)。
我們接著使用卜瓦松迴歸模型調整歷史效應之影響,模型估計歷史效應約貢獻每年6%之胃萎縮下降趨勢,調整歷史效應後介入預防胃萎縮效果估計為61%,與先前以發生率比較估計之效益相似。對於腸組織化生,歷史效應約可貢獻每年6%之下降趨勢,結果仍顯示介入無法預防腸組織化生。我們再使用卜瓦松迴歸模型分析1995–2008年胃癌發生率之長期趨勢,歷史效應約可貢獻每年10%之下降趨勢,介入後2004–2008年與介入前1995–2003年相較,胃癌發生率下降了41%,然仍未達統計上之顯著水準 (P=0.09)。除菌治療對於逆流性食道炎發生及惡化卻有顯著影響,除菌治療後食道炎發生率每人年為6% (95%CI: 5.1–6.9%)。本研究結果證實介入對於預防胃萎縮之效果卓越,此模型可外推至其他高風險族群。 根據論文第一章節大規模除菌治療伴隨逆流性食道炎之增加,本論文第二部份使用2003–2006年台大醫院健康管理中心內視鏡長期追蹤資料,使用含有隨機效應之馬可夫多階段模型來量化胃食道逆流症自然病史,評估代謝性風險因子對於其自然病程之影響,立意對此新興疾病設計預防策略。於2003–2006年之期間內我們共收集了3,669位重複接受上消化道內視鏡篩檢之民眾,我們使用均質性時間連續性之三階段馬可夫模型分析此長期追蹤資料,結果顯示連續三次之篩檢間隔中分別有12.2%、14.9%及17.9%之受檢者由正常食道黏膜進展為糜爛性食道炎,而有42.5%、37.3%及34.6%由輕度食道炎回復正常,模型推估轉移速率為:正常者每年有0.151人次 (95%CI: 0.136–0.165) 於次年產生輕度食道炎,而輕度食道炎患者每年有0.079人次 (95%CI: 0.063–0.094) 於次年進展至重度食道炎,而輕度食道炎患者每年也有0.481人次 (95%CI: 0.425–0.536) 回復正常;然而,重度食道炎患者若無接受妥善藥物治療,將無回復機會;多變數迴歸模型顯示男性 (相對危險性:4.31)、抽菸 (1.2)、以及代謝症候群 (1.75),會增加罹患食道炎之風險,而短期之組織胺第二型受器拮抗劑或氫離子幫浦抑制劑治療可增加食道炎回復正常之機會 (0.54),而有助於食道炎回復正常之歸因比可量化為:27%歸因於短期之藥物治療,而73%歸因於生活型態之調整,如戒菸、減重等作為。研究顯示胃食道逆流症與一般常見疾病相似,可表現出慢性進展及回復之自然病史,於群體中有一連串不同嚴重程度之臨床症狀,其異質性可由個體間風險因子多寡之不同,導致快慢不同之病程速率來解釋;了解代謝性風險因子之不良影響,對於此病症之預防及內視鏡資源妥善運用具有重要意義。 經由本論文第一部份,我們證實幽門桿菌除菌治療可預防胃萎縮之發生,進而加速胃癌風險之下降,然而有些民眾之胃炎變化卻已無法藉由除菌而改善,因此於論文之第三章節,我們將基於第一章節馬祖地區胃癌防治計畫之實際資料,使用第二章節之馬可夫多階段複迴歸比例風險模型訂定風險分數,建構於本人碩士論文模擬胃癌自然病史發展之馬可夫循環決策樹上,並模擬胃癌新興指標之效應用以克服族群異質性之問題。研究之防治策略包括:(1) 除菌治療作為胃癌初段預防工具、(2) 除菌治療後輔助一次內視鏡篩檢、(3) 除菌治療後視個體之風險分數及其接受篩檢之起始年齡訂定後續內視鏡定期篩檢。成本效益測量指標為多增加一單位之調整品質後存活人年所需要之額外花費,對於不同防治策略之間的相對成本效益比較,我們使用增量成本效果比來定量,我們也針對模型參數之不確定性進行進行單方向及機率性敏感度分析,每年的折扣率設定為3%。本研究總共模擬了60種情境,以進行各種策略之間比較,針對 30–50歲之中低風險族群,單一次之除菌治療無論是在台灣或是西方國家對於單位效益願意付出之最高費用之上限內,都佔有絕對優勢,而加上單一次內視鏡篩檢對此年輕族群並無好處。在於30–50歲高風險族群,除菌治療後定期內視鏡篩檢在上限為美金 $ 18,414元時,約有70–80%之機率可以符合成本效益。而於50–60歲之間,單一次的除菌治療效益逐漸下降,而相對地內視鏡檢查的效益開始提升。若是60–70歲才開始篩檢之年邁族群,因為此時無症狀之早期胃癌已開始出現,除菌治療後加上單一次的內視鏡篩檢早期胃癌,對於各種風險族群都轉變為最佳預防策略,而對於年邁的高風險族群,定期內視鏡篩檢符合成本效益之機率隨年齡逐漸下降,於70歲後才接受篩檢者,因為競爭死因之干擾,後續的定期內視鏡追蹤符合成本效益之機率下降至9%,而除菌治療加上單一次內視鏡篩檢則提高至90%。本研究結果可用以發展個人化健康經濟學模型,制定不同風險族群在不同篩檢年齡層之間的最佳胃癌防治策略,並可作為日後基礎科學與統計學上連結之橋樑。 | zh_TW |
dc.description.abstract | Although screening and treatment for Helicobacter pylori infection is considered a plausible approach for prevention of gastric cancer, few long-term population-based cohort studies have substantiated its efficacy. Gastric cancer prevention programs were implemented for Taiwanese adults residing on Matsu Island including endoscopic screening in 1996, 1998, 2004, and 2008 and treatment of Helicobacter pylori in 2004 and 2008. Main outcome measures were rates of occurrence of premalignant gastric lesions and gastric cancer. The results showed that the annual incidence rate of re-infection/recrudescence was estimated to be 1% (95%CI: 0.6–1.4%) per person-year following treatment. The prevalence of gastric atrophy declined from 60.8% in 2004 to 13.7% in 2008, and the annual incidence declined from 8.2% per person-year between 1996 and 2004 to 3.5% between 2004 and 2008, resulting in an overall efficacy of 57% (95%CI: 5%–81%; P=0.02). In contrast, during the same time study period, the prevalence of intestinal metaplasia was 31.3% and 38.9% with incidence rate of 4.7% and 6.1% per person-year, indicating the lack of intervention effectiveness. The average five-year incidence of gastric cancer declined from 40.3 to 30.4 per 100,000 person-years, resulting in an overall efficacy of 25% but not statistically significant (P=0.21).
Then, we applied Poisson regression models to estimate the treatment efficacy, making allowance of history effect. The results showed that an annual 6.2% decline was attributed to the history effect for both gastric atrophy and intestinal metaplasia. The efficacy in preventing gastric atrophy was estimated to be 61%, which was consistent with previous estimation based on the incidence rate ratio, while the intervention still failed to prevent intestinal metaplasia. Over the whole study period of 1995–2008, the natural decline of gastric cancer incidence was estimated to be 10% per year. Before and after intervention, the decline of gastric cancer incidence was 41% but not statistically significant (P=0.09). The incidence rate of esophagitis was however 6% (95%CI: 5.1–6.9%) following treatment. In conclusion, population-based screening and treatment for Helicobacter pylori infection is associated with successful prevention of gastric atrophy at the expense of increased esophagitis. Furthermore, it appears promising for prevention of gastric cancer especially in high-risk populations. Following the fact that that gastroesophageal reflux disease increased following Helicobacter pylori eradication, the second part of the dissertation aimed to quantify the natural course of gastroesophageal reflux disease and identify the risk factors associated with disease emergence and progression, in order to design the individual-tailored preventive strategies for this modern disease. A hospital database of 3,669 subjects undergoing repeated upper endoscopy was used. The presence and severity of endoscopic esophagitis have been diagnosed according to the Los Angeles classification. Data were analyzed using a three-state continuous time Markov model to estimate transition rates regarding the natural course of the disease. Individual risk score together with the kinetic curve was derived by identifying significant factors responsible for the net force between progression and regression. The results showed that during three consecutive study periods, 12.2%, 14.9%, and 17.9% of subjects, respectively, progressed from non-erosive to erosive disease, whereas 42.5%, 37.3%, and 34.6%, respectively, regressed to the non-erosive stage. The annual transition rate from non-erosive to class A-B disease was 0.151 per person year (95%CI: 0.136–0.165) and from class A-B to C-D was 0.079 per person year (95%CI: 0.063–0.094). The regression rate from class A-B to non-erosive disease was 0.481 per person year (95%CI: 0.425–0.536). Class C-D, however, appeared to be an absorbing state when not properly treated. Being male (relative risk [RR]: 4.31; 95%CI: 3.22–5.75), smoking (RR: 1.20; 95%CI: 1.03–1.39), or metabolic syndrome (RR: 1.75; 95%CI: 1.29–2.38) independently increased the likelihood of progressing from non-erosive to an erosive stage of disease and/or lowered the likelihood of disease regression. The short-term use of acid suppressants (RR: 0.54; 95% CI: 0.39–0.75) raised the likelihood of regression from erosive to non-erosive disease. Short-term treatment effect accounted for 27% disease regression and lifestyle modification was responsible for 73%. We concluded that the intraesophageal damage is a dynamic and migratory process in which the metabolic syndrome is associated with accelerated progression to or attenuated regression from erosive states. The derived risk score can be generalized to the population residing on the Matsu Island for the design of effective prevention and screening strategies for the gastroesophageal reflux disease. As the first part of dissertation showed that the benefit of screening and treatment for Helicobacter pylori infection varied from person to person, we designed individualized prevention strategies and evaluated their cost-effectiveness. Base-case estimates, including parameters of natural history, efficacy of intervention, and relevant cost, were derived from the Matsu Gastric-Cancer Chemoprevention Study. Cost-effectiveness was compared between chemoprevention with and without the adjunct of one-time endoscopic screening or periodic endoscopic surveillance. Population was stratified by the demographic data, molecular markers, and initial screening age. The main outcome measure was cost per quality-adjusted life-year gained with a 3% annual discount rate. A total of 60 scenarios were evaluated. Regarding the low- and average-risk groups, one-time chemoprevention was the strategy of choice for the adults aged 30–50 years over conventional levels of willingness to pay. During 50–60 years of age, the benefit of chemoprevention declined but the value of additional endoscopy increased. Above 60 years of age, chemoprevention followed by one-time endoscopy became the strategy of choice. Regarding the high-risk group, chemoprevention followed by periodic endoscopic surveillance had the highest probability of being cost-effective; however, the value of surveillance decreased from the age of 70 years due to competing risks. The above findings were robust to the sensitivity analyses. In conclusion, an individual-tailored strategy is cost-effective providing that the endoscopic resource can be properly allocated through risk assessment. Future inputs of basic research are therefore anticipated. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T21:46:50Z (GMT). No. of bitstreams: 1 ntu-99-D95842007-1.pdf: 3661810 bytes, checksum: 8681824138f7d4141b2b23abf1b5e882 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 vi 圖目錄 xiii 表目錄 xiv 第一章 前言 1 第二章 文獻回顧 4 2.1 篩檢及治療幽門螺旋桿菌感染對於胃癌自然病史之影響 5 2.1.1 胃癌之流行病學 5 2.1.2 胃癌多階段多因子之自然病史 7 2.1.3 量化胃癌自然病史 8 2.1.4 幽門螺旋桿菌感染與胃癌風險之相關性 9 2.1.5 治療幽門螺旋桿菌感染以預防胃癌之臨床研究 10 2.1.6 胃癌防治策略之可行性及可能侷限 12 2.2 胃食道逆流症之自然病史與防治之道 14 2.2.1 幽門螺旋桿菌除菌治療與胃食道逆流症之因果關係 14 2.2.2 胃食道逆流症多階段多因子之自然病史 15 2.2.3 量化胃食道逆流疾病之自然病史 16 2.2.4 胃食道逆流疾病防治策略之可行性及可能侷限 18 2.3 胃癌個人化防治策略之經濟面評估 19 2.3.1 胃癌防治策略之人口學指標 19 2.3.2 胃癌防治策略之基因指標 20 2.3.3 胃癌防治策略之基因外指標 20 2.3.4 胃癌防治策略之蛋白質體指標 21 2.3.5 胃癌個人化防治策略之可行性及可能侷限 21 第三章 研究材料與方法 25 3.1 篩檢及治療幽門螺旋桿菌感染對於胃癌自然病史之影響 26 3.1.1 馬祖胃癌防治計畫之資料型態 26 3.1.2 胃癌防治計畫之研究設計 27 3.1.3 胃炎雪梨病理分類之一致性 27 3.1.4 除菌治療後之細菌再發率 28 3.1.5 除菌治療前後胃腸病變盛行率之比較 28 3.1.6 個人化因子對於除菌治療效果之影響 28 3.1.7 量化除菌治療之長期效益 29 3.1.8 調整歷史效應 29 3.2 胃食道逆流症之自然病史與防治之道 30 3.2.1 健康管理中心之資料型態 30 3.2.2 內視鏡胃食道交口處診斷之一致性 31 3.2.3 馬可夫多階段模型 32 3.2.4 生活型態調整對於食道炎回復之歸因比例 32 3.2.5 馬可夫比例風險模型 33 3.3 胃癌個人化防治策略之經濟面評估 33 3.3.1 胃癌防治效益指標 33 3.3.2 胃癌防治成本指標 33 3.3.3 馬可夫多階段模型 34 3.3.4 胃癌個人化風險公式 34 3.3.5 胃癌個人化防治策略之模型架構 35 3.3.6 成本效益分析 37 第四章 研究結果 38 4.1 篩檢及治療幽門螺旋桿菌感染對於胃癌自然病史之影響 39 4.1.1 馬祖胃癌防治計畫之敘述性統計 39 4.1.2 除菌治療前後癌前病變之盛行率比較 39 4.1.3 除菌治療前後逆流性食道炎之盛行率比較 39 4.1.4 除菌治療對於降低幽門螺旋桿菌感染之效益 40 4.1.5 除菌治療對於預防癌前病變之效益 40 4.1.6 除菌治療對於預防胃癌之效益 41 4.1.7 調整歷史效應後除菌治療對於癌前病變之淨效益 41 4.1.8 調整歷史效應後除菌治療對於胃癌之淨效益 41 4.2 胃食道逆流症之自然病史與防治之道 42 4.2.1 健康管理中心族群之敘述性統計 42 4.2.2 胃食道逆流症自然病史轉移速率之量化 42 4.2.3 馬可夫多階段動態曲線之建構與模型適合度檢定 43 4.2.4 馬可夫單因子迴歸模型 44 4.2.5 馬可夫複迴歸模型與風險公式之架構 44 4.2.6 馬可夫多階段模型之外推性 45 4.3 胃癌個人化防治策略之經濟面評估 46 4.3.1 基準值分析 46 4.3.2 單方向敏感度分析 47 4.3.3 蒙地卡羅參數模擬散佈圖 47 4.3.4 接受度曲線分析 48 第五章 討論 50 5.1 篩檢及治療幽門螺旋桿菌感染對於胃癌自然病史之影響 51 5.1.1 本研究之主要發現 51 5.1.2 本研究結果與電腦模擬性研究之比較 51 5.1.3 歷史效應之影響 52 5.1.4 幽門螺旋桿菌除菌治療與逆流性食道炎之消長 52 5.1.5 本研究實驗設計之優勢及侷限 53 5.1.6 本研究之結論 54 5.2 胃食道逆流症之自然病史與防治之道 55 5.2.1 本研究之主要發現 55 5.2.2 胃食道逆流症自然病史 55 5.2.3 胃食道逆流症危險因子之探討 56 5.2.4 本研究統計方法之優勢及侷限 56 5.2.5 本研究之結論 57 5.3 胃癌個人化防治策略之經濟面評估 57 5.3.1 本研究之主要發現 58 5.3.2 風險評估對於健康經濟學模型之貢獻 58 5.3.3 年齡分級對於健康經濟學模型之貢獻 58 5.3.4 本研究之可能侷限 59 5.3.5 本研究之結論 59 參考文獻 121 附錄 135 | |
dc.language.iso | zh-TW | |
dc.title | 族群性篩檢及治療幽門螺旋桿菌感染對於胃癌與胃食道逆流症自然病史之影響與其經濟評估 | zh_TW |
dc.title | Effect of Population-Based Screening and Treatment of Helicobacter pylori Infection on the Natural Course of Gastric Cancer and Gastroesophageal Reflux Disease and the Economic Evaluation | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張淑惠,戴政,劉宏輝,胡琮輝,于承平,鄭宗記 | |
dc.subject.keyword | 胃癌防治,幽門螺旋桿菌,干涉時間序列實驗設計,胃食道逆流症,馬可夫多階段模型,成本效益分析, | zh_TW |
dc.subject.keyword | gastric cancer prevention,Helicobacter pylori,interrupted time-series design,gastroesophageal reflux disease,Markov multistate model,cost-effectiveness analysis, | en |
dc.relation.page | 135 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2010-08-05 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf | 3.58 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。